Literature DB >> 26150250

Effect of the stop-flow technique on cardiac retention of c-kit positive human cardiac stem cells after intracoronary infusion in a porcine model of chronic ischemic cardiomyopathy.

Matthew C L Keith1, Yukichi Tokita, Xian-Liang Tang, Shahab Ghafghazi, Joseph B Moore, Kyung U Hong, Julius B Elmore, Alok R Amraotkar, Haixun Guo, Brian L Ganzel, Kendra J Grubb, Michael P Flaherty, Bathri N Vajravelu, Marcin Wysoczynski, Roberto Bolli.   

Abstract

It is commonly thought that the optimal method for intracoronary administration of cells is to stop coronary flow during cell infusion, in order to prolong cell/vascular wall contact, enhance adhesion, and promote extravasation of cells into the interstitial space. However, occlusion of a coronary artery with a balloon involves serious risks of vascular damage and/or dissection, particularly in non-stented segments such as those commonly found in patients with heart failure. It remains unknown whether the use of the stop-flow technique results in improved donor cell retention. Acute myocardial infarction was produced in 14 pigs. One to two months later, pigs received 10 million indium-111 oxyquinoline (oxine)-labeled c-kit(pos) human cardiac stem cells (hCSCs) via intracoronary infusion with (n = 7) or without (n = 7) balloon inflation. Pigs received cyclosporine to prevent acute graft rejection. Animals were euthanized 24 h later and hearts harvested for radioactivity measurements. With the stop-flow technique, the retention of hCSCs at 24 h was 5.41 ± 0.80 % of the injected dose (n = 7), compared with 4.87 ± 0.62 % without coronary occlusion (n = 7), (P = 0.60). When cells are delivered intracoronarily in a clinically relevant porcine model of chronic ischemic cardiomyopathy, the use of the stop-flow technique does not result in greater myocardial cell retention at 24 h compared with non-occlusive infusion. These results have practical implications for the design of cell therapy trials. Our observations suggest that the increased risk of complications secondary to coronary manipulation and occlusion is not warranted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26150250      PMCID: PMC8274540          DOI: 10.1007/s00395-015-0503-8

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  29 in total

1.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

Authors:  Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting
Journal:  Circulation       Date:  2011-11-07       Impact factor: 29.690

2.  Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.

Authors:  Emerson C Perin; James T Willerson; Carl J Pepine; Timothy D Henry; Stephen G Ellis; David X M Zhao; Guilherme V Silva; Dejian Lai; James D Thomas; Marvin W Kronenberg; A Daniel Martin; R David Anderson; Jay H Traverse; Marc S Penn; Saif Anwaruddin; Antonis K Hatzopoulos; Adrian P Gee; Doris A Taylor; Christopher R Cogle; Deirdre Smith; Lynette Westbrook; James Chen; Eileen Handberg; Rachel E Olson; Carrie Geither; Sherry Bowman; Judy Francescon; Sarah Baraniuk; Linda B Piller; Lara M Simpson; Catalin Loghin; David Aguilar; Sara Richman; Claudia Zierold; Judy Bettencourt; Shelly L Sayre; Rachel W Vojvodic; Sonia I Skarlatos; David J Gordon; Ray F Ebert; Minjung Kwak; Lemuel A Moyé; Robert D Simari
Journal:  JAMA       Date:  2012-03-24       Impact factor: 56.272

Review 3.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

4.  A highly sensitive and accurate method to quantify absolute numbers of c-kit+ cardiac stem cells following transplantation in mice.

Authors:  Kyung U Hong; Qian-Hong Li; Yiru Guo; Nikita S Patton; Afsoon Moktar; Aruni Bhatnagar; Roberto Bolli
Journal:  Basic Res Cardiol       Date:  2013-04-03       Impact factor: 17.165

5.  Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up.

Authors:  Bojan Vrtovec; Gregor Poglajen; Luka Lezaic; Matjaz Sever; Dragoslav Domanovic; Peter Cernelc; Aljaz Socan; Sonja Schrepfer; Guillermo Torre-Amione; François Haddad; Joseph C Wu
Journal:  Circ Res       Date:  2012-10-12       Impact factor: 17.367

Review 6.  Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials.

Authors:  Michael J Lipinski; Giuseppe G L Biondi-Zoccai; Antonio Abbate; Reena Khianey; Imad Sheiban; Jozef Bartunek; Marc Vanderheyden; Hyo-Soo Kim; Hyun-Jae Kang; Bodo E Strauer; George W Vetrovec
Journal:  J Am Coll Cardiol       Date:  2007-10-15       Impact factor: 24.094

7.  Dynamic tracking during intracoronary injection of 18F-FDG-labeled progenitor cell therapy for acute myocardial infarction.

Authors:  Brendan Doyle; Brad J Kemp; Panithaya Chareonthaitawee; Cynthia Reed; Jeffrey Schmeckpeper; Paul Sorajja; Stephen Russell; Philip Araoz; Stephen J Riederer; Noel M Caplice
Journal:  J Nucl Med       Date:  2007-10       Impact factor: 10.057

8.  Safety of intracoronary infusion of 20 million C-kit positive human cardiac stem cells in pigs.

Authors:  Matthew C L Keith; Xian-Liang Tang; Yukichi Tokita; Qian-Hong Li; Shahab Ghafghazi; Joseph Moore Iv; Kyung U Hong; Brandon Elmore; Alok Amraotkar; Brian L Ganzel; Kendra J Grubb; Michael P Flaherty; Gregory Hunt; Bathri Vajravelu; Marcin Wysoczynski; Roberto Bolli
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

9.  Morphologic expression of the left coronary artery in pigs. An approach in relation to human heart.

Authors:  Fabian Alejandro Gómez; Luis Ernesto Ballesteros
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Apr-Jun

10.  Global intracoronary infusion of allogeneic cardiosphere-derived cells improves ventricular function and stimulates endogenous myocyte regeneration throughout the heart in swine with hibernating myocardium.

Authors:  Gen Suzuki; Brian R Weil; Merced M Leiker; Amanda E Ribbeck; Rebeccah F Young; Thomas R Cimato; John M Canty
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

View more
  8 in total

1.  Nonocclusive multivessel intracoronary infusion of allogeneic cardiosphere-derived cells early after reperfusion prevents remote zone myocyte loss and improves global left ventricular function in swine with myocardial infarction.

Authors:  Gen Suzuki; Brian R Weil; Rebeccah F Young; James A Fallavollita; John M Canty
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

Review 2.  Targeted delivery of therapeutic agents to the heart.

Authors:  Susmita Sahoo; Taro Kariya; Kiyotake Ishikawa
Journal:  Nat Rev Cardiol       Date:  2021-01-26       Impact factor: 32.419

3.  Widespread Intracoronary Cardiopoietic Cell Infusion: Treating at the Time of Myocardial Reperfusion to Prevent Rather Than Reverse Established Left Ventricular Dysfunction Moves Us Closer to Practical Clinical Translation.

Authors:  John M Canty; Brian R Weil; Gen Suzuki
Journal:  Circ Res       Date:  2016-04-01       Impact factor: 17.367

4.  Safety of intracoronary infusion of 20 million C-kit positive human cardiac stem cells in pigs.

Authors:  Matthew C L Keith; Xian-Liang Tang; Yukichi Tokita; Qian-Hong Li; Shahab Ghafghazi; Joseph Moore Iv; Kyung U Hong; Brandon Elmore; Alok Amraotkar; Brian L Ganzel; Kendra J Grubb; Michael P Flaherty; Gregory Hunt; Bathri Vajravelu; Marcin Wysoczynski; Roberto Bolli
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

5.  Time course of VCAM-1 expression in reperfused myocardial infarction in swine and its relation to retention of intracoronary administered bone marrow-derived mononuclear cells.

Authors:  André Uitterdijk; Bianca C W Groenendijk; Charlotte Gorsse-Bakker; Anna Panasewicz; Stefan Sneep; Dennie Tempel; Esther H van de Kamp; Daphne Merkus; Willem J van der Giessen; Dirk J Duncker
Journal:  PLoS One       Date:  2017-06-19       Impact factor: 3.240

Review 6.  In Vivo Tracking of Cell Therapies for Cardiac Diseases with Nuclear Medicine.

Authors:  Mayra Lorena Moreira; Priscylla da Costa Medeiros; Sergio Augusto Lopes de Souza; Bianca Gutfilen; Paulo Henrique Rosado-de-Castro
Journal:  Stem Cells Int       Date:  2016-01-12       Impact factor: 5.443

7.  Histone Deacetylase 1 Depletion Activates Human Cardiac Mesenchymal Stromal Cell Proangiogenic Paracrine Signaling Through a Mechanism Requiring Enhanced Basic Fibroblast Growth Factor Synthesis and Secretion.

Authors:  Joseph B Moore; John Zhao; Annalara G Fischer; Matthew C L Keith; David Hagan; Marcin Wysoczynski; Roberto Bolli
Journal:  J Am Heart Assoc       Date:  2017-07-05       Impact factor: 5.501

8.  A Novel Biological Strategy for Myocardial Protection by Intracoronary Delivery of Mitochondria: Safety and Efficacy.

Authors:  Borami Shin; Mossab Y Saeed; Jesse J Esch; Alvise Guariento; David Blitzer; Kamila Moskowitzova; Giovanna Ramirez-Barbieri; Arzoo Orfany; Jerusha K Thedsanamoorthy; Douglas B Cowan; James A Inkster; Erin R Snay; Steven J Staffa; Alan B Packard; David Zurakowski; Pedro J Del Nido; James D McCully
Journal:  JACC Basic Transl Sci       Date:  2019-12-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.